©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Nerve Growth Factor Binding Site on TrkA Mapped to a Single 24-Amino Acid Leucine-rich Motif (*)

(Received for publication, January 10, 1995; and in revised form, August 31, 1995)

Jörg M. Windisch Rainer Marksteiner Rainer Schneider (§)

From the Institute of Biochemistry, University of Innsbruck, Peter-Mayr-Straße 1a, 6020 Innsbruck, Austria

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The extracellular domains of the TrkA nerve growth factor (NGF) receptor and its homologs harbor a modular mosaic of potential ligand binding motifs, namely two immunoglobulin (Ig)-like modules and an LRM(3) cassette consisting of a tandem array of three leucine-rich motifs (LRMs) flanked by cysteine-rich clusters (Schneider, R., and Schweiger, M. (1991) Oncogene 6, 1807-1811). Identification of a structural motif capable of specifically recognizing the various neurotrophins was achieved by assessing their affinities to isolated recombinant modules of TrkA and TrkB. In both receptors the LRM(3) cassette alone could mediate the respective neurotrophin selectivities and affinities. Further tracking down of this NGF-binding site in TrkA strikingly revealed that a single LRM of 24 amino acids could bind NGF selectively with nanomolar affinity. Since this is the first example of a single LRM with a highly specific, well defined function, it might serve as a valuable tool to elucidate the general structural requirements of substrate recognition and high affinity binding in the large superfamily of LRM-containing proteins.


INTRODUCTION

Nerve growth factor (NGF) (^1)was the first growth factor to be discovered over 40 years ago(2) . It belongs to the growing family of neurotrophins that promote the survival and differentiation of distinct neuronal populations(3, 4, 5, 6) . Neurotrophins bind to two discrete receptor types, which can be distinguished pharmacologically. p75 binds all known neurotrophins with similar nanomolar affinities(7, 8) , whereas cells expressing TrkA, a tyrosine kinase receptor originally identified as a human oncogene(9) , bind solely NGF and exhibit significantly slower dissociation kinetics(10, 11) .

There are two receptors homologous to TrkA, namely TrkB and TrkC, which are correlated with the binding of other neurotrophins. TrkB is a receptor for three distinct ligands, brain-derived neurotrophic factor (BDNF)(12) , neurotrophin-3 (NT-3)(5) , and neurotrophin-4 (NT-4)(13) . TrkC exclusively binds NT-3(14) . Although only cells expressing Trk-type receptors show functional responses upon neurotrophin binding (15, 16) , it is still a matter of debate whether the binding phenomena observed in different cellular systems (17, 18, 19, 20) are solely due to the action of these receptors (21, 22) or rather to larger protein complexes involving the concerted action of additional components such as p75. Other imponderabilities of cell culture-based systems arise from internalization events, temperature dependence, lysosomal degradation, and cell type-specific differences. This prompted us to conduct a systematic biochemical characterization of isolated receptor modules to achieve a clear assignment of affinities and kinetic properties to defined molecular structures.

The extracellular ligand-binding domains of receptor tyrosine kinases harbor various protein-protein interaction motifs that potentially function in ligand binding and/or receptor dimerization(1, 23, 24) . In many cases mutations in the extracellular domains lead to a ligand-independent constitutive activation of the receptor(25, 26, 27) . In the case of Trk-type receptors the modular structure of the extracellular domain was elucidated by the application of sequence comparison algorithms (1) capable of detecting even highly degenerate motifs(28) . Several distinct protein modules were identified that could serve as docking sites for either neurotrophins or other components involved in a functional receptor complex(1) . Among these are immunoglobulin-like domains and leucine-rich motif (LRM)-containing regions.

LRMs are short amino acid sequences (22-30 residues) that are repeated in tandem in an individual protein and contain hydrophobic residues at conserved positions(29) . In the case of Trk-type receptors, there are three tandem LRM repeats of, on the average, 24 residues in the N-terminal region of the molecule that are flanked by two cysteine-rich regions, so-called cysteine clusters(1) . LRM repeats are potent mediators of strong and specific homo- and heterophilic protein-protein interactions. They have been found in proteins as diverse as human platelet glycoprotein IX(30) , Drosophila Toll(31) , and Drosophila Chaoptin(32) , where they mediate cell-cell interactions and communication, and yeast adenylate cyclase, where they form the interaction site with the Ras protein(33) . This clear involvement of LRM repeats in protein-protein interactions made them highly interesting candidates for the NGF binding site within the TrkA receptor.

On the other hand, immunoglobulin-like domains are firmly established as potent ligand binding domains. The keratinocyte growth factor receptor(34) , the macrophage colony-stimulating factor receptor(35) , and the intercellular adhesion molecule 1 (ICAM-1) (36) are prominent examples of receptors that utilize Ig-like domains for ligand binding. Recently two groups have shown independently that the immunoglobulin-like domains of TrkA, TrkB, and TrkC play quantitatively important roles in the binding of the neurotrophin ligands and in the activation of the receptors(37, 38) .


EXPERIMENTAL PROCEDURES

Cloning and Expression of Receptor Modules

The regions coding for the TrkA/B domains were amplified from rat/mouse brain mRNA by reverse transcription-polymerase chain reaction and cloned into the pMal-p expression vector. The sequences of the fragments were identical to the ones published in (19) and (39) . The recombinant maltose binding protein (MBP)-TrkA/B fusion proteins were expressed in Escherichia coli and purified essentially as described in the manufacturer's protocol (New England Biolabs, 1990). For the negative controls a fusion protein composed of MBP and beta-galactosidase (MBP-betaGal) was expressed. The purified proteins were extensively dialyzed against 20 mM Tris-Cl, pH 7.4, 200 mM NaCl, 1 mM EDTA (column buffer) before they were used in the experiments.

Neurotrophins

Mouse submaxillary gland NGF-beta was purchased from Sigma. Recombinant E. coli and vaccinia virus-expressed mouse BDNF and mouse NT-3 (40) were kind gifts of R. Kolbeck and Y.-A. Barde. I-NGF-beta and I-BDNF were prepared using the lactoperoxidase method (see ``Acknowledgements'') or purchased from Amersham Corp.

Binding Assays Using Receptor Affinity Columns

100 µg (1.5 nmol) of fusion protein were loaded onto a 100-µl amylose resin column equilibrated with column buffer. After washing with 10 column volumes of the same buffer containing 5 mg/ml bovine serum albumin and 0.1 mg/ml cytochrome (bovine heart) to prevent nonspecific binding to the column material and with another 20 column volumes of the above buffer without protein, 2 µg of the respective neurotrophin in 100 µl of column buffer were loaded onto the column. To determine whether the applied neurotrophin had bound to the respective immobilized Trk domain, 15 µl of the flow-through were loaded onto a 10-20% SDS-polyacrylamide gradient gel. After electrophoresis the gels were silver-stained according to Heukeshoven and Dernick(41) . A reduction in the strength of the neurotrophin band as compared with the flow-through of the corresponding control column (with immobilized betaGal-MBP) represents specific binding of the neurotrophin to the respective Trk domain. The application of column buffer containing 10 mM maltose led to the co-elution of the bound neurotrophins with the recombinant receptor components as determined by SDS-polyacrylamide gel electrophoresis and silver staining. These gels are not shown in this paper because, in addition to the neurotrophins, the eluted fractions contained a greater than 50-fold excess of the respective receptor protein, making it impossible to produce a perspicuous figure.

Equilibrium Binding Assays

100 ng (1.25 pmol) of recombinant protein/assay were batch loaded onto 5 µl of amylose resin in 25 µl of column buffer. After centrifuging, the supernatants were removed, and the pellets were washed three times with column buffer. In order to minimize nonspecific binding, the column material was resuspended in 90 µl of column buffer, 5 mg/ml bovine serum albumin, 0.1 mg/ml cytochrome c (bovine heart), 2 mg/ml heat-denatured bovine serum albumin, 0.1 mg/ml heat-denatured cytochrome c and incubated with gentle shaking for 30 min. The denatured proteins were included to give a more solid amylose resin pellet after centrifugation. 5 µl of I-NGF at different concentrations were added and incubated with gentle shaking at 20 °C for 90 min to reach equilibrium binding. Final concentrations of I-NGF ranged from 7.8125 times 10 to 4 times 10M. Each binding reaction was carried out in duplicate, and for each concentration of I-NGF a MBP-betaGal control was made to detect nonspecific binding to MBP. Differences between duplicate values were generally very small. After centrifuging for 3 min, the supernatants were transferred to fresh tubes (SN1). The pellets were washed three times in column buffer containing 20 mM maltose to elute the receptor-ligand complexes. The supernatants of all three centrifugation steps were combined in a new tube (SN2). SN1, SN2, and the amylose resin pellet were measured on a ``Cobra Auto Gamma'' counter (Packard). SN1, therefore, represented free I-NGF, SN2 corresponded to specifically bound I-NGF. The small amounts of radioactivity trapped in the pellet were added to the free I-NGF. Nonspecific binding to the MBP in the control experiments was low and subtracted from the specific binding in each case.

Essentially the same experiment was conducted with the other receptor domains of TrkA and TrkB (using I-BDNF). For the binding reactions 1.25 pmol or 2.5 pmol of receptor protein were used.

Kinetics of Association

Binding reactions were prepared as described above and contained 1.25 pmol of receptor/100 µl. The start volume of all reactions was 700 µl. The reactions were brought to final concentrations of I-NGF ranging from 5 times 10M to 2 times 10M. Aliquots of 100 µl were taken at the different time points (0, 2, 4, 8, 16, 32, and 64 min) and processed as described above. All data points are means of duplicates. The data are corrected for nonspecific binding. Nonspecific binding was <25% of total binding at very low concentrations of NGF and early time points and <15% for all other data points.

Kinetics of Dissociation

Binding reactions of 700 µl were prepared and brought to equilibrium binding as described above. Each reaction contained 2.5 pmol of receptor/100 µl. Concentrations of I-NGF ranged from 5 times 10M to 4 times 10M. Dissociation of I-NGF was induced by the addition of a 100-fold excess of unlabeled NGF. Aliquots of 100 µl were taken at the different time points (0, 2, 5, 15, 30, 60, and 90 min) and processed as described above. All data points are means of duplicates.

Calculations of the K(d) and the kinetic values were performed according to Rodriguez-Tebar and Barde (42) using the GraFit program (Erithacus).


RESULTS AND DISCUSSION

The goal of this study was to investigate the distinct roles these individual structural modules of Trk-type receptors play in the binding of neurotrophin and how strong of a contribution these receptors make in generating high affinity binding. For an initial experiment, the entire extracellular domains of TrkA and TrkB were expressed in recombinant soluble form and purified as described under ``Experimental Procedures.'' Immobilized on a column, these recombinant domains were found to exhibit the same ligand binding specificities observed in the cellular system(5, 12, 18) , i.e. NGF bound to TrkA, and BDNF and NT-3 bound to TrkB. This is direct evidence that Trk proteins can specifically bind neurotrophins in the absence of their intracellular kinase domain and without membrane attachment or contribution of other receptor components.

Quantification of the affinities of neurotrophins to the recombinant extracellular domains using binding assays with I-NGF and I-BDNF (see ``Experimental Procedures'') led to K(d) values of 10M for the respective ligand-receptor pairs (NGF-TrkA and BDNF-TrkB) (Table 1). No affinity of I-NGF to TrkB and of I-BDNF to TrkA was detected (Table 1), which verifies the finding of high binding specificity in Trk receptors described above. These results directly show that the NGF binding sites with nanomolar K(d) values observed in NIH 3T3, COS, and NR18 cells ectopically expressing TrkA (16, 18) can be attributed entirely to the affinity of the TrkA receptor. The same is true for the BDNF-TrkB interaction. The nanomolar affinities observed by us for this ligand-receptor pair are in good agreement with the data obtained by Dechant et al.(43) for A293 cells ectopically expressing chick TrkB and by Soppet et al.(12) for NIH 3T3 cells ectopically expressing rat TrkB, the receptor used in this work.



Scatchard plot analyses of the interactions of I-NGF with the TrkA extracellular domain (Fig. 1) and of I-BDNF with the respective region of TrkB (data not shown) revealed no binding sites with affinities in the range of 10M as observed on NIH 3T3-derived cell lines overexpressing TrkA (44) or even in the picomolar range as exhibited by chick embryonic sensory neurons (17) and other neuronal cells. No affinities of I-NGF to TrkB and of I-BDNF to TrkA could be detected (Table 1). In vivo more than 50% of the extracellular domains of Trk receptors are made up of carbohydrates. Our studies with non-glycosylated recombinant proteins suggest that glycosylation does not enhance the affinity and specificity of the Trk-neurotrophin interactions but they do not exclude the possibility that glycosylation may reduce ligand-binding affinity, possibly even in a regulatory mechanism.


Figure 1: Scatchard plot analysis of the equilibrium binding of I-NGF to the recombinant soluble TrkA extracellular domain. The experiments were carried out with immobilized recombinant receptor proteins as described under ``Experimental Procedures.'' Final concentrations of I-NGF ranged from 7.8125 times 10 to 4 times 10M. Each binding reaction was carried out in duplicate, and for each concentration of I-NGF a MBP-betaGal control was made to detect nonspecific binding to MBP. Differences between duplicate values were generally very small.



The first step in the identification of the ligand binding sites of TrkA and TrkB was the expression of the two major structural components of their extracellular domains, the LRM(3) cassette and the Ig2 domain. As mentioned above, both types of structures have been shown to be capable of exerting strong and specific protein-protein interactions(29, 34, 35, 36, 45, 46) and thus were good candidates for the ligand binding site. The recombinant domains were immobilized on column matrices, and their ability to bind NGF, BDNF, and NT-3 was tested (Fig. 2).


Figure 2: Panel A, the E. coli-expressed TrkA and TrkB Ig2-domains exhibit no neurotrophin binding. The experiments were carried out using affinity columns with immobilized recombinant receptor modules as described under ``Experimental Procedures.'' The respective neurotrophin was loaded onto the column, and the flow-through was analyzed by SDS-polyacrylamide gel electrophoresis and silver staining. A reduction in the strength of the neurotrophin band as compared with the flow-through of the corresponding control column (with immobilized betaGal-MBP) represents specific binding of the neurotrophin to the respective Trk domain. Binding of all neurotrophins to the Ig2-domains of their non-natural receptors (i.e. NGF to TrkB and BDNF/NT-3 to TrkA) was also tested, but no affinities were detected. A, MBP-TrkA-Ig2-domain; B, MBP-TrkB-Ig2-domain; -, controls (MBP-betaGal). B, selective neurotrophin binding by the LRM(3) cassettes of TrkA/TrkB. The experiments were performed as described in the legend to panel A. A, MBP-TrkA-LRM(3) cassette; B, MBP-TrkB-LRM(3) cassette; -, controls (MBP-betaGal).



The binding experiments with the recombinant Ig2-domains revealed no detectable affinity of NGF, BDNF, or NT-3 to this segment of any of the two Trk receptors investigated (Fig. 2A). Additional binding assays using I-NGF and I-BDNF (Table 1) confirmed these results. Therefore, our experiments did not support a role of the Ig2-domain in the binding of NGF to TrkA and the binding of BDNF and NT-3 to TrkB, but rather suggested the LRM(3) cassette as the major neurotrophin binding site. Since the immunoglobulin-like domains have recently been shown to significantly contribute to ligand binding in Trk receptors (37, 38) we assume the lack of glycosylation or some other system-inherent problem prevented the binding of NGF to the immunoglobulin-like domains in our assays. We therefore concentrated on investigating the role of the N-terminal LRM(3) cassette in Trk receptor function.

This structural entity of TrkA and TrkB could still discriminate between NGF, BDNF, and NT-3 in that the LRM(3) cassette of TrkA specifically bound NGF (but not BDNF and NT-3) and the LRM(3) cassette of TrkB specifically bound BDNF and NT-3 (but not NGF) (Fig. 2B). These results demonstrate that the LRM(3) cassettes of TrkA and TrkB contain neurotrophin binding sites displaying the same ligand binding specificities as the entire receptors. Quantitative binding assays revealed that the LRM(3) cassettes of TrkA and TrkB bind I-NGF and I-BDNF, respectively, with the same nanomolar affinities as the complete recombinant extracellular domains (Table 1).

Since the expression of trkB-derived proteins is significantly hampered by their high toxicity to E. coli, we chose TrkA to systematically trace down the exact location of a neurotrophin binding site. Creating appropriate expression vector constructs, the two cysteine clusters flanking the LRM(3) cassette were removed first (L) followed by the elimination of the first (LC(2)) and the third (C(1)L) LRM repeat in two separate approaches. All these soluble recombinant receptor proteins showed the same nanomolar affinities and specificities for I-NGF (Table 1), suggesting that the 24 amino acids of the middle LRM are sufficient to constitute a ligand binding site.

This could be demonstrated by the expression of three further fusion proteins, the isolated second LRM (L(2)) and two proteins disrupting the second LRM in the very center from opposite sides (C(1)L and LC(2)). The L(2) region exhibited full binding affinity (K(d) for I-NGF approx 10M) and specificity, being able to discriminate between NGF, BDNF, and NT-3 in that no affinity of L(2) for the latter two neurotrophins was detected (Table 1). Scatchard plot analysis revealed the existence of a single type of binding site (data not shown). In contrast, C(1)L and LC(2) showed no detectable affinity for I-NGF andI-BDNF (Table 1). These data unambiguously identify the 24-amino acid L(2) leucine-rich motif as an NGF binding site within the TrkA receptor.

The sequence of this region of rat TrkA as well as of the corresponding region of rat TrkB is shown in Fig. 3. The two sequences are 54% identical, leaving 11 residues to account for the ligand binding specificity observed in our experiments. The second LRM is the only repeat in Trk-type receptors that matches perfectly with the general LRM consensus sequence making it a classic structural and functional unit.


Figure 3: Leucine-rich motifs and the NGF binding site of TrkA. The first two lines show an alignment of the second LRM from TrkA and TrkB. The third line is the consensus of both sequences. The last line shows the general consensus sequence of a leucine-rich motif.



To investigate in more detail what part of the binding characteristics of the NGF receptor complex observed in the cellular system can be attributed to TrkA or, more precisely, to an unprecedentedly small ligand binding site of TrkA, the binding kinetics of the recombinant TrkA extracellular domain as well as of L(2) were examined and compared with the data that have been determined for different in vivo systems.

The kinetics of association of L(2) with I-NGF were found to be complex (Fig. 4A). The relationship between the observed association rate (k) and the ligand concentration is linear at low concentrations of NGF (5 times 10 to 4 times 10M), allowing the calculation of a k close to 1 times 10^7M s (Fig. 4A). At higher concentrations of ligand (around the K(d)) a mechanism of negative cooperativity seems to take effect again, leading to a linear relationship between k and NGF concentration, allowing the calculation of a second k value of about 3 times 10^5M s (Fig. 4A). These data correlate well with the ones obtained with the recombinant extracellular domain. The on rate that was observed at low concentrations of ligand is akin to that observed on PC12 cells(48) . Experiments by Mahadeo et al.(49) using mutants of PC12 cells lacking p75 indicated that in vivo p75 may in some way assist TrkA in recruiting ligand since only in the presence of this second neurotrophin receptor were k values in the range of 10^7M s observed. Our results indicate that TrkA may be sufficient to generate on rates in this range even though such a mechanism seems to only be effective at low concentrations of ligand.


Figure 4: The binding kinetics of I-NGF to the 24-amino acid second LRM of TrkA are equivalent to the ones observed for the entire recombinant extracellular domain. A, kinetics of association. The observed association rates (k) were calculated from the times at which half of the equilibrium binding was reached (k = ln 2/t) and plotted against the total concentrations of NGF. The k values were obtained from the slopes of the regression lines. Binding reactions were prepared as described under ``Experimental Procedures.'' The reactions were brought to final concentrations of I-NGF ranging from 5 times 10M to 2 times 10M. Aliquots were taken at the different time points and processed as described above. All data points are means of duplicates. The data are corrected for nonspecific binding. The k values for the second LRM of TrkA (L(2), circle) and the TrkA extracellular domain (bullet) were (8.54 ± 1.37 times 10^6)/(2.87 ± 0.68 times 10^5) M s and (7.03 ± 1.03 times 10^6)/(2.53 ± 0.72 times 10^5) M s, respectively. B, kinetics of dissociation. Binding reactions were prepared and brought to equilibrium binding as described under ``Experimental Procedures.'' Concentrations of I-NGF ranged from 5 times 10 to 4 times 10M. Dissociation of I-NGF was induced by the addition of a 100-fold excess of unlabeled NGF. Aliquots were taken at the different time points and processed as described above. All data points are means of duplicates. Two separate curves can be drawn through the above data leading to two different t and k values for each data set. The data for the second LRM of TrkA (L(2), bullet) and the TrkA extracellular domain (Ex, circle) were almost identical, with t and k values of 16/110 min and (5 times 10)/(1 times 10 s), respectively.



The dissociation kinetics revealed a similarly complex scenario apparently displaying a curve composed of two separable components (Fig. 4B). For this reason, as for the association rates, two different half-lives (16 and 110 min) for the ligand-receptor complex and two different k (5 times 10 s and 1 times 10 s) values could be calculated, again with L(2) exhibiting the same behavior as the entire extracellular domain of TrkA (Fig. 4B). Remarkably, not only this biphasic behavior but also the measured values are in good agreement with the ones observed by Meakin et al.(19) in COS cells expressing rat TrkA (half-lives of 10 and 90 min, respectively). All of these values clearly represent slow dissociation kinetics, indicating that the second leucine-rich motif may be involved in determining the complex kinetics of dissociation that define TrkA as the ``slow NGF receptor''(50) .

The molecular mechanism of this complex behavior with respect to the kinetics of association and dissociation is as yet unclear. The observed negative cooperativity may somehow be correlated to the formation of di- or oligomeric receptor complexes. Preliminary results from our laboratory show that the L(2) fusion protein is capable of forming oligomers in solution, albeit probably with lower efficiency than the entire extracellular domain. (^2)Taking into account the concentration of the recombinant proteins in the assays it seems quite possible that also in this system most of the L(2) proteins are present in di-/oligomeric form. These dimers could bind two NGF dimers with different kinetics, the first being bound with a faster on rate than the second. Whatever the mechanism, the measured values are consistent with the equilibrium binding constant determined by us.

Therefore, as summarized in Fig. 5, a single leucine-rich motif of TrkA not only shows the same affinities for NGF as the full-length recombinant TrkA receptor but also displays the same extraordinary kinetic properties. The binding characteristics of the TrkA receptor are apparently not dependent on glycosylation as far as the LRM(3) cassette is concerned. The E. coli expressed modules show functionality, and the middle LRM is active even though it is normally located between two potential glycosylation sites(1) . The carbohydrate chains attached to these sites may be a reason why other groups (37, 38) using different in vitro and heterologous in vivo systems were unable to detect the interaction observed by us. On neurons there may be a mechanism during receptor activation that exposes the second LRM so it is accessible for NGF and can fulfill its biological role.


Figure 5: The structure of Trk-type receptors and NGF binding. A, schematic structural organization of Trk-type tyrosine kinase receptors(1) . B, mapping of an NGF binding site in TrkA to a 24-amino acid leucine-rich motif. The abbreviations in this figure are the same as in Table 1.



Our studies, however, did not demonstrate binding affinities in the range of 5-10 pM as have been described for some cell lines overexpressing TrkA receptors(10, 44) . It has been suggested that this high affinity binding may be a result of the formation of di-/oligomeric complexes that represent the activated state of most receptor tyrosine kinases(10) . Even though the recombinant protein corresponding to the Trk extracellular domains is capable of forming homodi-/oligomers in vitro,^2 we cannot, with respect to the fairly high ratio of available MBP docking sites on the immobilizing matrix to the amount of Trk-MBP protein present, exclude the possibility that the number of active Trk di-/oligomers in this experimental system is too low for high affinity in the picomolar range to be detected. The observation of negative cooperativity in binding, however, is a good indication that di-/oligomers are indeed formed in our system.

An interesting possibility arising from our results is that the promiscuity observed in Trk-type receptors might be based on the allocation of the binding sites for the different neurotrophins to distinct LRMs within the LRM(3) cassette. This would, for example, allow different neurotrophins to simultaneously bind to one and the same Trk-type receptor.

Finally, the recently determined three-dimensional structure of an LRM protein (51) offers ideal opportunities for molecular modelling studies on the detailed interaction mechanism not only in the case of Trk-type receptors and neurotrophins but in general for the whole superfamily of LRM containing proteins and their substrates. Hence, the precise mapping of this binding site for NGF in TrkA receptors could facilitate the design of new neurotrophic drugs with enhanced performance and a wider range of supported neurons for the efficient treatment of damaged nerves after injuries or in the course of neurodegenerative diseases.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 01143-512-507-5273; Fax 01143-512-507-2894; rainer.schneider@uibk.ac.at.

(^1)
The abbreviations used are: NGF, nerve growth factor; NGFR, NGF receptor; BDNF, brain-derived neurotrophic factor; NT-3, neurotrophin-3; NT-4, neurotrophin-4; LRM, leucine-rich motif; MBP, maltose binding protein; betaGal, beta-galactosidase; ICAM-1, intercellular adhesion molecule 1; SN, supernatant.

(^2)
R. Marksteiner, J. M. Windisch, and R. Schneider, unpublished observations.


ACKNOWLEDGEMENTS

We thank Y.-A. Barde for critically reading the manuscript and helpful discussions; A. Schröpel, G. Dechant, and R. Kolbeck for supplying recombinant (iodinated) NGF, BDNF, and NT-3 and for help with establishing and interpreting the binding assays; E. M. Shooter for kind permission to obtain rat trkA clones from G. Dechant and A. Obermeier; B. Auer for general support, inspiring discussions, and continuous encouragement; and the Institute of Pharmacology, University of Innsbruck Medical School, for letting us use their -counter.


REFERENCES

  1. Schneider, R., and Schweiger, M. (1991) Oncogene 6, 1807-1811 [Medline] [Order article via Infotrieve]
  2. Levi-Montalcini, R. (1987) Science 237, 1154-1162 [Medline] [Order article via Infotrieve]
  3. Thoenen, H. (1991) Trends Neurosci. 14, 165-170 [CrossRef][Medline] [Order article via Infotrieve]
  4. Raffioni, S., Bradshaw, R. A., and Buxser, S. E. (1993) Annu. Rev. Biochem. 62, 823-850 [CrossRef][Medline] [Order article via Infotrieve]
  5. Barbacid, M. (1993) Oncogene 8, 2033-2042 [Medline] [Order article via Infotrieve]
  6. Götz, R., Köster, R., Winkler, C., Raulf, F., Lottspeich, F., Schard, M., and Thoenen., H. (1994) Nature 372, 266-269 [CrossRef][Medline] [Order article via Infotrieve]
  7. Rodriguez-Tebar, A., Dechant, G., and Barde, Y.-A. (1990) Neuron 4, 487-492 [Medline] [Order article via Infotrieve]
  8. Barker, P. A., and Murphy, R. A. (1992) Mol. Cell. Biochem. 110, 1-15 [Medline] [Order article via Infotrieve]
  9. Martin-Zanca, D., Hughes, S. H., and Barbacid, M. (1986) Nature 319, 743-748 [Medline] [Order article via Infotrieve]
  10. Jing, S., Tapley, P., and Barbacid, M. (1992) Neuron 9, 1067-1079 [Medline] [Order article via Infotrieve]
  11. Loeb, D. M., and Greene, L. A. (1993) J. Neurosci. 13, 2919-2929 [Abstract]
  12. Soppet, D., Escandon, E., Maragos, J., Middlemas, D. S., Reid, S. W., Bair, J., Burton, L. E., Stanton, B. R., Kaplan, D. R., Hunter, T., Nikolics, K., and Parada, L. F. (1991) Cell 65, 895-903 [Medline] [Order article via Infotrieve]
  13. Klein, R., Lamballe, F., Bryant, S., and Barbacid, M. (1992) Neuron 8, 947-956 [Medline] [Order article via Infotrieve]
  14. Lamballe, F., Klein, R., and Barbacid, M. (1991) Cell 66, 967-979 [Medline] [Order article via Infotrieve]
  15. Rovelli, G., Heller, R. A., Canossa, M., and Shooter, E. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8717-8721 [Abstract/Free Full Text]
  16. Loeb, D. M., Maragos, J., Martin-Zanca, D., Chao, M. V., Parada, L. F., and Greene, L. A. (1991) Cell 66, 961-966 [Medline] [Order article via Infotrieve]
  17. Sutter, A., Riopelle, R. J., Harris-Warrick, R. M., and Shooter, E. M. (1979) J. Biol. Chem. 254, 5972-5982 [Abstract]
  18. Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., and Parada, L. F. (1991) Science 252, 554-558 [Medline] [Order article via Infotrieve]
  19. Meakin, S. O., Ueli, S., Drinkwater, C. C., Welcher, A. A., and Shooter, E. M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2374-2378 [Abstract]
  20. Hempstead, B. L., Martin-Zanca, D., Kaplan, D. R., Parada, L. F., and Chao, M. (1991) Nature 350, 678-683 [CrossRef][Medline] [Order article via Infotrieve]
  21. Ibanez, C. F., Ebendal, T., Barbany, G., Murray-Rust, J., Blundell, T. L., and Persson, H. (1992) Cell 69, 329-341 [Medline] [Order article via Infotrieve]
  22. Drinkwater, C. C., Suter, U., Angst, C., and Shooter, E. M. (1991) Proc. R. Soc. Lond. B Biol. Sci. 246, 307-313 [Medline] [Order article via Infotrieve]
  23. Schneider, R. (1992) Trends Biochem. Sci. 17, 468-469 [CrossRef][Medline] [Order article via Infotrieve]
  24. Ullrich, A., and Schlessinger, J. (1990) Cell 61, 203-212 [Medline] [Order article via Infotrieve]
  25. Coulier, F., Kumar, R., Ernst, M., Klein, R., Martin-Zanca, D., and Barbacid, M. (1990) Mol. Cell. Biol. 10, 4202-4210 [Medline] [Order article via Infotrieve]
  26. Mulligan, L. M., Kwok, J. B., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., Ponder, M. A., Telenius, H., Tunnacliffe, A., and Ponder, B. A. (1993) Nature 363, 458-460 [CrossRef][Medline] [Order article via Infotrieve]
  27. Sprenger, F., and Nüsslein-Volhard, C. (1992) Cell 71, 987-1001 [Medline] [Order article via Infotrieve]
  28. Schneider, R., Unger, G., Stark, R., Schneider-Scherzer, E., and Thiel, H.-J. (1993) Science 261, 1169-1171 [Medline] [Order article via Infotrieve]
  29. Schneider, R., Schneider-Scherzer, E., Thurnher, M., Auer, B., and Schweiger, M. (1988) EMBO J. 7, 4151-4156 [Abstract]
  30. Hickey, J., Williams, S. A., and Roth, G. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 6773-6777 [Abstract]
  31. Keith, F. J., and Gay, N. J. (1990) EMBO J. 9, 4299-4306 [Abstract]
  32. Krantz, D. E., and Zipursky, S. L. (1990) EMBO J. 9, 1969-1977 [Abstract]
  33. Suzuki, N., Choe, H. R., Nishida, Y., Yamawaki-Kataoka, Y., Ohnishi, S., Tamaoki, T., and Kataoka, T. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8711-8715 [Abstract]
  34. Yayon, A., Zimmer, Y., Guo-Hong, S., Avivi, A., Yarden, Y., and Givol, D. (1992) EMBO J. 11, 1885-1890 [Abstract]
  35. Wang, Z., Myles, G. M., Brandt, C. S., Lioubin, M. N., and Rohrschneider, L. (1993) Mol. Cell. Biol. 13, 5348-5359 [Abstract]
  36. Diamond, M. S., Staunton, D. E., Marlin, S. D., and Springer, T. A. (1991) Cell 65, 961-971 [Medline] [Order article via Infotrieve]
  37. Perez, P., Coll, P. M., Hempstead, B. L., Martin-Zanca, D., and Chao, M. V. (1995) Mol. Cell. Neurosci. 6, 97-105 [CrossRef][Medline] [Order article via Infotrieve]
  38. Urfer, R., Tsoulfas, P., O'Connell, L., Shelton, D. L., Parada, L. F., and Presta, L. G. (1995) EMBO J. 14, 2795-2805 [Abstract]
  39. Klein, R., Parada, L. F., Coulier, F., and Barbacid, M. (1989) EMBO J. 8, 3701-3709 [Abstract]
  40. Götz, R., Kolbeck, R., Lottspeich, F., and Barde, Y.-A. (1992) Eur. J. Biochem. 204, 745-749 [Abstract]
  41. Heukeshoven, J., and Dernick, R. (1985) Electrophoresis 6, 103-112
  42. Rodriguez-Tebar, A., and Barde, Y.-A. (1988) J. Neurosci. 8, 3337-3342 [Abstract]
  43. Dechant, G., Biffo, S., Okazawa, H., Kolbeck, R., Pottgiesser, J., and Barde, Y.-A. (1993) Development 119, 545-558 [Abstract/Free Full Text]
  44. Klein, R., Jing, S., Nanduri, V., O'Rourke, E., and Barbacid, M. (1991) Cell 65, 189-197 [Medline] [Order article via Infotrieve]
  45. Braun, T., Schofield, R., and Sprengel, R. (1991) EMBO J. 10, 1885-1890 [Abstract]
  46. Hofsteenge, J., Kieffer, B., Matthies, R., Hemmings, B. A., and Stone, S. R. (1988) Biochemistry 27, 8537-8544 [Medline] [Order article via Infotrieve]
  47. Middlemas, D. S., Lindberg, R. A., and Hunter, T. (1991) Mol. Cell. Biol. 11, 143-153 [Medline] [Order article via Infotrieve]
  48. Sonnenfeld, K. H., and Ishii, D. N. (1985) J. Neurosci. 5, 1717-1728 [Abstract]
  49. Mahadeo, D., Kaplan, L., Chao, M. V., and Hempstead, B. L. (1994) J. Biol. Chem. 269, 6884-6891 [Abstract/Free Full Text]
  50. Schechter, A. L., and Bothwell, M. A. (1981) Cell 24, 867-874 [Medline] [Order article via Infotrieve]
  51. Kobe, B., and Deisenhofer, J. (1993) Nature 366, 751-756 [CrossRef][Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.